A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy

Lancet

Volumn 367, Issue 9521, 2006, Pages 1495-1502

  Stebbing, Justin ^a   Sanitt, Adam ^a   Nelson, Mark ^a   Powles, Tom ^a   Gazzard, Brian ^a   Bower, Mark ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; CD4 ANTIGEN; CYTIDINE DERIVATIVE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL MODEL; SURVIVAL; VALIDATION PROCESS;

EID: 33646172829     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68649-2     Document Type: Article

References (56)

1. Palella Jr. F., Delaney K., Moorman A., et al., for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338 (1998) 853-860
2. Sterne J., Hernan M., Ledergerber B., et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366 (2005) 378-384
3. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 92 (2000) 1823-1830
4. Portsmouth S., Stebbing J., Gill J., et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 17 (2003) F17-F22
5. Stebbing J., Gazzard B., Mandalia S., et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 22 (2004) 2177-2183
6. Friedman-Kien A., Laubenstein L., Rubinstein P., et al. Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med 96 (1982) 693-700
7. Clifford G., Polesel J., Rickenbach M., et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 97 (2005) 425-432
8. Chang Y., Cesarman E., Pessin M., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266 (1994) 1865-1869
9. Koch R. Über die ätiologie der tuberkulose. Verhandlungen des kongresses für innere medizin (1882), Erster Kongress, Wiesbaden
10. Whitby D., Howard M., Tenant-Flowers M., et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet 346 (1995) 799-802
11. Flore O., Rafii S., Ely S., O'Leary J., Hyjek E., and Cesarman E. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 394 (1998) 588-592
12. Ensoli B., Gendelman R., Markham P., et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 371 (1994) 674-680
13. Reitz Jr. M., Nerurkar L., and Gallo R. Perspective on Kaposi's sarcoma: facts, concepts, and conjectures. J Natl Cancer Inst 91 (1999) 1453-1458
14. Stebbing J., Portsmouth S., and Gazzard B. How does HAART lead to the resolution of Kaposi's sarcoma?. J Antimicrob Chemother 51 (2003) 1095-1098
15. Bower M., Nelson M., Young A., et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 23 (2005) 5224-5228
16. Stebbing J., Bower M., and Srivastava P. Kaposi's sarcoma as a model for cancer immunotherapy. Trends Mol Med 10 (2004) 187-193
17. Sgadari C., Barillari G., Toschi E., et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8 (2002) 225-232
18. Ensoli B., Barillari G., Salahuddin S., Gallo R., and Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345 (1990) 84-86
19. Mariotti M., Castiglioni S., and Maier J. Expression analysis and modulation by HIV-Tat of the tyrosine phosphatase HD-PTP. J Cell Biochem 98 (2006) 301-308
20. Krown S., Metroka C., Wernz J., and for the AIDS Clinical Trials Group Oncology Committee. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 7 (1989) 1201-1207
21. Krown S., Testa M., Huang J., and for the AIDS Clinical Trials Group Oncology Committee. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. J Clin Oncol 15 (1997) 3085-3092
22. Holkova B., Takeshita K., Cheng D., et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 19 (2001) 3848-3851
23. Nasti G., Talamini R., Antinori A., et al. AIDS-related Kaposi's Sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era-the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol 21 (2003) 2876-2882
24. Krown S. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 22 (2004) 399-402
25. Nasti G., and Tirelli U. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma (KS): implications for the design of therapeutic trials in patients with advanced symptomatic KS. J Clin Oncol 23 (2005) 2433
26. Stebbing J., Mazhar D., Lewis R., et al. The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma. Ann Oncol 17 (2005) 503-506
27. Yeni P., Hammer S., Carpenter C., et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288 (2002) 222-235
28. Pozniak A., Gazzard B., Anderson J., et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 4 suppl 1 (2003) 1-41
29. Yeni P., Hammer S., Hirsch M., et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292 (2004) 251-265
30. Andersen P., and Gill R. Cox's regression model for counting processes, a large sample study. Ann Stat 10 (1982) 1100-1120
31. Gill R. Understanding Cox's regression model. Experientia Suppl 41 (1982) 187-199
32. Venables W., and Ripley B. Modern applied statistics with S-PLUS. 3rd edn. (1999), Springer, New York
33. Fleming T., and Lin D. Survival analysis in clinical trials: past developments and future directions. Biometrics 56 (2000) 971-983
34. Kaplan E., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
35. Cox D. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
36. Harrell Jr. F., Lee K., Califf R., Pryor D., and Rosati R. Regression modelling strategies for improved prognostic prediction. Stat Med 3 (1984) 143-152
37. Steyerberg E., Eijkemans M., Harrell Jr. F., and Habbema J. Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets. Med Decis Making 21 (2001) 45-56
38. Royston P. A strategy for modelling the effect of a continuous covariate in medicine and epidemiology. Stat Med 19 (2000) 1831-1847
39. Hothorn T., and Lausen B. On the exact distribution of maximally selected rank statistics, computational statistics and data analysis. Comput Stat Data Analysis 43 (2003) 121-137
40. Schwarz G. Estimating the dimension of a model. Ann Stat 6 (1978) 461-464
41. Efron B., and Tibshirani R. Bootstrap methods for standard errors, confidence intervals and other measures of statistical accuracy. Stat Sci 1 (1986) 54-75
42. Steyerberg E., Harrell Jr. F., Borsboom G., Eijkemans M., Vergouwe Y., and Habbema J. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 54 (2001) 774-781
43. Harrell Jr. F., Lee K., and Mark D. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361-387
44. Justice A., Covinsky K., and Berlin J. Assessing the generalizability of prognostic information. Ann Intern Med 130 (1999) 515-524
45. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
46. Hasenclever D., Diehl V., and for the International Prognostic Factors Project on Advanced Hodgkin's Disease. A prognostic score for advanced Hodgkin's disease. N Engl J Med 339 (1998) 1506-1514
47. Solal-Celigny P., Roy P., Colombat P., et al. Follicular lymphoma international prognostic index. Blood 104 (2004) 1258-1265
48. Bower M., Gazzard B., Mandalia S., et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 143 (2005) 265-273
49. Linton P., and Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 5 (2004) 133-139
50. Spano J., Salhi Y., Costagliola D., Rozenbaum W., and Girard P. Factors predictive of disease progression and death in AIDS-related Kaposi's sarcoma. HIV Med 1 (2000) 232-237
51. Quinlivan E., Zhang C., Stewart P., Komoltri C., Davis M., and Wehbie R. Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis 185 (2002) 1736-1744
52. Engels E., Biggar R., Marshall V., et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma. AIDS 17 (2003) 1847-1851
53. Marcelin A., Gorin I., Morand P., et al. Quantification of Kaposi's sarcoma-associated herpesvirus in blood, oral mucosa, and saliva in patients with Kaposi's sarcoma. AIDS Res Hum Retroviruses 20 (2004) 704-708
54. Bourboulia D., Aldam D., Lagos D., et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18 (2004) 485-493
55. Nasti G., Martellotta F., Berretta M., et al. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 98 (2003) 2440-2446
56. Soulier J., Grollet L., Oksenhendler E., et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86 (1995) 1276-1280